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Percutaneous atherectomy was ﬁrst introduced as an
alternative to balloon angioplasty (BA) in 1986 to improve
the results that could be achieved with BA [1]. The
advantages of atherectomy were the creation of a smooth
luminal surface with less local thrombosis and the reduc-
tion of elastic recoil because the lumen can widen without
stretching the arterial wall. In percutaneous atherectomy
the atheromatous intima usually occurs with or without the
media. The notion that the ‘‘bad’’ atheroma would be
removed is also an appealing feature of this technique.
Atherectomy can be divided into extirpative atherec-
tomy, which means cutting and/or shaving and removing
the atherosclerotic material from the patient, and ablative
atherectomy, where the atheroma is fragmented with a
high-speed device. The Simpson atherectomy catheter is an
example of extirpative atherectomy, and the Kensey cath-
eter and the rotablator are examples of ablative devices.
The term ‘‘directional’’ means that the catheter removes
one sector or direction of the vessel-wall atheroma.
Eleven studies of the Simpson atherectomy device were
published between 1988 and 1993. Excluding 2 studies that
did not publish technical success, a total of 908 patients
were reported. The technical success rate was reported at
approximately 90%, and complications, mainly peripheral
embolisation, were reported to be between 3% and 21%
(median 4%).
Six-month follow-up was available in eight reports, and
patency by different deﬁnitions varied between 80% and
99%. Twelve-month follow-up of 71% to 94% was
reported in only ﬁve reports. Only one article reported 24-
month follow-up of a lager group of patients. The 24-
months patency has since decreased to 37% [2].
The previous papers is typical for older interventional
radiology (IR) publications concentrating on the technique
but with less focus on long-term outcome or real evidence
for effectiveness. In 1995, Vroegindeweij et al. [3] pub-
lished data from a prospective randomized trial comparing
BA with atherectomy. This is an example of probably the
earliest randomized controlled trial (RCT) concerning
peripheral interventional techniques. Although the total
series is small (n = 73 patients), the outcome is clear and
signiﬁcant. Atherectomy does not result in improved clin-
ical and hemodynamic outcome. Furthermore, atherectomy
of segmental atherosclerotic femoropopliteal disease does
not result in a better patency rate than BA; in patients with
lesions longer than 2 cm, atherectomy results are signiﬁ-
cantly worse.
So, the myth was busted and that was the end of
directional atherectomy, one could say. However, it is well
known that IR is a profession of the future, so we should
never look back. Yes, directional atherectomy publications
died out during the next 2 decades; then in approximately
2005, a well-orchestrated new directional atherectomy
offensive began. The system was presented as ‘‘new’’ and
promising. There was an early registry and enthusiastic
presentations at many angioclubs, and IR meetings were
held by small groups of physicians [4]. Again, directional
atherectomy was booming once again. This time not only
medical journals were involved, there was also a publica-
tion in the Wall Street Journal in August 2005: Physicians
Testing SilverHawk Catheter Also Own Stock Options was
the title of the warning article. Twelve doctors supplied
information about the catheter’s effectiveness to a registry
that the company used to evaluate the SilverHawk (EV3,
USA)—its only product—and to promote it to other
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DOI 10.1007/s00270-008-9437-ydoctors. The article concluded with the warning that the
results were anecdotal.
By now (2008), new reports have shown that directional
atherectomy, also performed with the ‘‘new’’ device, has no
additional value to BA but moreover carries a high risk for
peripheral embolization, which was not noted in the original
registry [5–7]. Is the myth now ﬁnally busted? Some myths
must be busted twice. However, in IR you never know.
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